New Paper in Science Reports Discovery of Ultrapotent Chemogenetic Approach that Forms Scientific Foundation for Redpin Therapeutics’ Technology
Retrieved on:
Thursday, March 14, 2019
Scott Sternson, Ph.D., Group Leader at the Janelia Research Campus of the Howard Hughes Medical Institute (HHMI), led the study.
Key Points:
- Scott Sternson, Ph.D., Group Leader at the Janelia Research Campus of the Howard Hughes Medical Institute (HHMI), led the study.
- Redpin Therapeutics has a worldwide exclusive license from HHMI for therapeutic use of this technology.
- The researchers developed a novel method for engineering ligand-gated ion channel receptors to have ultrapotent sensitivity to U.S. Food and Drug Administration (FDA)-approved agonists.
- These chemogenetic receptors enable the selective control of cells in vivo, which Redpin is developing for potential clinical therapies.